If you have been reading about research peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
== Growth and cultivation == Sophora flavescens is an evergreen slow growing shrub growing to 1.5 m (5 ft) by 1 m (3.3 ft). It is hardy to 0–10 °F (−18 – −12 °C) and to US zone 6. The plant prefers light (sandy), medium (loamy) and heavy (clay) soils and requires well-drained soil. The plant prefers acid, neutral and basic (alkaline) soils. It cannot grow in the shade. It requires moist soil. Like many other species in the family Fabaceae, this species can fix nitrogen.
==== Immune suppressants ==== The steroid prednisone might also be used to achieve a better result, but it can lead to the worsening of symptoms and takes weeks to achieve its maximal effectiveness. Research suggests that up to 15% of people with myasthenia gravis do not positively respond to immune suppressants. Due to the myriad symptoms that steroid treatments can cause, it is not the preferred method of treatment. Other immune suppressing medications may also be used including rituximab,azathioprine and especially mycophenolate. Nipocalimab (Imaavy) was approved for medical use in the United States in April 2025.
Free movement of goods within the European Union is achieved by a customs union, and the principle of non-discrimination. The EU manages imports from non-member states, duties between member states are prohibited, and imports circulate freely. In addition under the Treaty on the Functioning of the European Union article 34, 'Quantitative restrictions on imports and all measures having equivalent effect shall be prohibited between Member States'. In Procureur du Roi v Dassonville the Court of Justice held that this rule meant all "trading rules" that are "enacted by Member States" which could hinder trade "directly or indirectly, actually or potentially" would be caught by article 34. This meant that a Belgian law requiring Scotch whisky imports to have a certificate of origin was unlikely to be lawful. It discriminated against parallel importers like Mr Dassonville, who could not get certificates from authorities in France, where they bought the Scotch. This "wide test", to determine what could potentially be an unlawful restriction on trade, applies equally to actions by quasi-government bodies, such as the former "Buy Irish" company that had government appointees. It also means states can be responsible for private actors. For instance, in Commission v France French farmer vigilantes were continually sabotaging shipments of Spanish strawberries, and even Belgian tomato imports. France was liable for these hindrances to trade because the authorities 'manifestly and persistently abstained' from preventing the sabotage.
Sources: en.wikipedia.org
Tensions continued in late April 2025 after the spread of an offensive audio recording allegedly containing blasphemous content against the Islamic prophet Muhammad, allegedly attributed to a Druze scholar named Marwan Kiwan, who disavowed it.
==== Common causes of chronic wounds ==== Diabetes mellitus – Wound healing impairment in the setting of diabetes is multifactorial. Hyperglycemia, neuropathy, microvascular complications, impaired immune and inflammatory responses, and psychological factors have all been implicated in the formation and propagation of diabetic wounds. Feet are the most common location of diabetic wounds, although any type of wound can be negatively impacted by diabetes. It has been estimated that up to 25% of patients with diabetes mellitus will be affected by non-healing wounds in their lifetime. Venous/Arterial insufficiency – Impaired blood outflow (venous) or inflow (arterial) can both impair wound healing, thereby causing chronic wounds. Much like diabetes, venous/arterial insufficiency most commonly result in chronic wounds of the lower extremities. In chronic venous insufficiency, blood pooling impedes oxygen exchange and creates a chronic pro-inflammatory environment which both promote formation of venous ulcers. Peripheral artery disease, on the other hand, causes wounds due to poor blood inflow and typically affects the most distal extremities (fingers, toes). Immunologic disease – The immune system plays a critical role in the inflammatory process; therefore, any disease of the immune system has the potential to impair the inflammatory phase of wound healing, thereby leading to a chronic wound. Patients suffering from diseases such as rheumatoid arthritis and lupus have been found to have larger wounds and prolonged time to heal when compared to the general population.
Medical cannabis, or medical marijuana, refers to the use of herbal cannabis or its preparations to treat disease or improve symptoms. There is no single agreed-upon definition (e.g., cannabinoids derived from cannabis and synthetic cannabinoid analogs are also used). The rigorous scientific study of cannabis as a medicine has been hampered by production restrictions and by the fact that it is classified as an illegal drug by many governments. Evidence supports only a few approved uses of cannabinoids and most medical claims, such as efficacy for insomnia or acute pain, lack sufficient evidence; benefits, risks, and harm-reduction strategies should be evaluated before clinical recommendations of cannabis or cannabinoids. There is some evidence suggesting cannabis can be used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, or to treat chronic pain and muscle spasms. Evidence for its use for other medical applications is insufficient for drawing conclusions about safety or efficacy. There is evidence supporting the use of cannabis or its derivatives in the treatment of chemotherapy-induced nausea and vomiting, neuropathic pain, and multiple sclerosis. Lower levels of evidence support its use for AIDS wasting syndrome, epilepsy, rheumatoid arthritis, and glaucoma. The medical use of cannabis is legal only in a limited number of territories, including Belgium, Australia, the Netherlands, New Zealand, Spain, and many U.S. states.
Sources: en.wikipedia.org
McGuinn's concept was jettisoned in favor of a country project, which included Parsons' songs "One Hundred Years from Now" and "Hickory Wind", and songs by Bob Dylan, Woody Guthrie and Merle Haggard. Recording sessions for Sweetheart of the Rodeo commenced at Columbia Records' recording studios in the Music Row area of Nashville on March 9, 1968. Mid-way through, the sessions moved to Columbia Studios, Hollywood and were completed on May 27, 1968. However, Parsons was still under contract to LHI Records and Hazlewood threatened legal action over Parsons' appearance on the album. As a result, McGuinn replaced three of Parsons' lead vocals with his own; in 1973, in an interview with Cameron Crowe, Parsons said that McGuinn "erased it and did the vocals himself and fucked it up." Parsons remained as lead vocalist on the songs "You're Still on My Mind", "Life in Prison", and "Hickory Wind". While in England with the Byrds in the summer of 1968, Parsons left the band over a planned concert tour of South Africa and his opposition to apartheid. During this period Parsons became acquainted with Mick Jagger and Keith Richards of The Rolling Stones. After leaving the band, Parsons stayed at Richards' house and the pair developed a close friendship, with Parsons reintroducing the guitarist to country music.
Millions of people are affected by hyperhidrosis, but more than half never receive treatment due to embarrassment, lack of awareness, or lack of concern. While it most commonly affects the armpits, feet, and hands, it is possible for someone to experience this condition over their whole body. The face is another common area for hyperhidrosis to be an issue. Sweating uncontrollably is not always expected and may be embarrassing to people with the condition. It can cause both physiological and emotional problems in patients. It is generally inherited. It is not life-threatening, but it is threatening to a person's quality of life. Treatments for hyperhidrosis include antiperspirants, iontophoresis, and surgical removal of sweat glands. In severe cases, botulinum toxin injections or surgical cutting of nerves that stimulate the excessive sweating (endoscopic thoracic sympathectomy) may be an option.
== Side effects == Although it is considered a "safe" medicine, it is, like sulpiride, strictly contraindicated for patients under the age of 18 due to its effects during the process of puberty. This is likely related to its side effects on levels of the hormone prolactin, which is involved in sexual development. There are also insufficient clinical data on the other side effects in adolescents. Tiapride has been found to cause excess prolactin levels in plasma, which can cause decreased libido, infertility and increased risk of breast cancer. This is because dopamine plays a primary role in regulating prolactin release by binding to D2 receptors on prolactin-secreting cells in the anterior pituitary. Thus, when tiapride blocks these receptors these cells are disinhibited and release more prolactin. The side-effect reported most commonly to the U.S. Food and Drug Administration (FDA) is rhabdomyolysis, a condition characterized by muscle tissue breakdown. Cardiac abnormalities such as prolongation of the QT interval and torsades de pointes have also been observed. Dosages above approximately 300 mg/day risk inducing tardive dyskinesia. However, given the drug's fairly wide window of tolerable doses, dosages can often be titrated to obtain the desired effect without bringing about motor deficits. In general, tiapride is considered an atypical antipsychotic because of its low risk for extrapyramidal symptoms, such as akinesia and akathisia.
palatal partial thickness flap palatal full-partial thickness flap tuberosity partial thickness flap Contrary to the donor site for a free gingival graft, the surgeon is able to achieve primary closure at the donor site for a SECT. Langer later described the SECT as a method by which to augment concavities and irregularities of the alveolar ridge following traumatic extractions, advanced periodontitis or developmental defects. Currently, though, such augmentation of hard tissue defects tends to be done with hard tissue replacements, namely bone graft materials. However, it was only in 1985 that Langer proposed the SECT for root coverage following gingival recession.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.